Is the polycystic ovary syndrome associated with chronic inflammation per se?

Olszanecka-Glinianowicz, Magdalena; Banaś, Michał; Zahorska-Markiewicz, Barbara; Janowska, Joanna; Kocełak, Piotr; Madej, Paweł; Klimek, Katarzyna

doi:10.1016/j.ejogrb.2006.10.037

Cited by 56 publications

(43 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar to the results of others [20,21,35], we found no evidence of increased levels of either hsCRP or TNF-α in a young, euglycaemic, eulipidemic, and normotensive population of PCOS women compared with controls. The most published data, but not all [20,[34][35][36], demonstrated increased levels of hsCRP in women with PCOS [10,11,[37][38][39], which are primarily dependent upon co-existent obesity [40].…”

Section: Discussionsupporting

confidence: 78%

“…Additionally, there are authors who consider PCOS as a pro-inflammatory state due to elevated plasma concentrations of inflammatory mediators of atherogenesis, such as interleukin (IL)-6, IL-18, soluble intercellular adhesion molecule-1 (sICAM-1), sEselectin, high sensitivity C-reactive protein (hsCRP), tumoral necrosis factor-alpha (TNF-α), monocyte chemotactic protein-1 (MCP-1), and plasminogen activator inhibitor-1 (PAI-1) [17][18][19]. However, there are also studies which have not confirmed the elevated levels of inflammatory markers in PCOS [20,21]. Moreover, a problem that has not yet been settled is the determining factors for vascular abnormalities and low-grade chronic inflammation in PCOS.…”

Section: Introductionmentioning

confidence: 95%

“…We prospectively studied 45 women with PCOS (age: 23.11± 4.14 (15)(16)(17)(18)(19)(20)(21)(22)(23), body mass index (BMI): 28.41±5.97 (15.62-40.74) kg/m 2 ), who were presented to our clinic. The study protocol was approved by the local ethics board and informed written consent was obtained from all participants.…”

Section: Study Protocolmentioning

confidence: 99%

“…A control group composed of 32 women (age: 23.06 ±5.37 (15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34), BMI: 25.87± 6.89 (16.88-42.86) kg/m 2 ) was selected as to be similar to the group of patients in terms of age and BMI. In the end though, our intention was not fully accomplished because there was still a significant difference in BMI between the groups.…”

Section: Study Protocolmentioning

confidence: 99%

See 3 more Smart Citations

The polycystic ovary syndrome (pcos) status and cardiovascular risk in young women

Ilie¹,

Pepene²,

Marian³

et al. 2010

Open Medicine

View full text Add to dashboard Cite

AbstractThe study investigated the presence of early vascular damage and chronic inflammation, and their relationships with hormonal and metabolic parameters in 45 young women with PCOS in comparison with thirty-two healthy age-matched controls. Hormonal and metabolic profiles, high sensitivity C-reactive protein (hsCRP), tumoral necrosis factor-alpha (TNF-α), endothelin-1 (ET-1), brachial flow-mediated vasodilation (FMD) and carotid intima-media thickness (CIMT) were determined in both groups. Compared with the controls, women with PCOS had significantly lower FMD and respectively higher ET-1 levels (p=0.001). No differences were observed between the groups in terms of CIMT or inflammatory markers. In the PCOS group, ET-1 levels were significantly correlated with only testosterone concentrations (r = 0.31, p = 0.037), whereas the hsCRP levels were independently predicted only by body mass index (BMI). Within the total group, the PCOS status was the sole significant predictor of ET-1 levels and the only independent predictor of FMD. In conclusion, there is evidence of endothelial dysfunction associated with increased levels of androgen hormones in young women with PCOS. The combination of endothelial dysfunction and coexistent obesity promoting inflammation contributes to the progression of atherogenesis in PCOS. The PCOS status should be regarded as a predictor marker of cardiovascular risk, along with well-known cardiovascular risk factors.

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Introductionmentioning

confidence: 95%

Section: Study Protocolmentioning

confidence: 99%

Section: Study Protocolmentioning

confidence: 99%

See 2 more Smart Citations

The polycystic ovary syndrome (pcos) status and cardiovascular risk in young women

Ilie¹,

Pepene²,

Marian³

et al. 2010

Open Medicine

View full text Add to dashboard Cite

show abstract

“…Excessive visceral fat depot and its hormonal disturbances seem to play a role in hormonal and metabolic disturbances in PCOS (28,29,30,31,32). As described earlier, the novel adipokine FGF21 may play a role in the PCOS-related metabolic disturbances.…”

Section: Introductionmentioning

confidence: 92%

Circulating FGF21 levels are related to nutritional status and metabolic but not hormonal disturbances in polycystic ovary syndrome

Olszanecka-Glinianowicz¹,

Madej²,

Wdowczyk³

et al. 2015

European Journal of Endocrinology

Self Cite

View full text Add to dashboard Cite

Objective: The aim of this study was to analyse relationships between plasma fibroblast growth factor 21 (FGF21) levels and nutritional status, and metabolic and hormonal disturbances in polycystic ovary syndrome (PCOS) women. Design and setting: A cross-sectional study involving 85 PCOS (48 obese) and 72 non-PCOS women (41 obese) was conducted to evaluate the relationship between FGF21 levels and PCOS. Methods: Anthropometric parameters and body composition were determined. In the fasting state; serum concentrations of glucose, androgens, FSH, LH, SHBG, insulin and FGF21 were measured. Results: Plasma FGF21 levels were significantly higher in obese women compared with normal-weight women in both PCOS and non-PCOS subgroups (120.3 (18.2-698) vs 62.3 (16.4-323.6) pg/ml, P!0.05 and 87.2 (12.9-748.4) vs 62.9 (18.0-378.8) pg/ml, P!0.05 respectively). Additionally, circulating FGF21 levels were significantly higher in the obese PCOS subgroup compared with the non-PCOS subgroup (120.3 (18.2-698.0) vs 87.2 (12.9-748.4) pg/ml, P!0.05). Circulating FGF21 levels were proportional to BMI (RZ0.27; P!0.001), body fat mass (RZ0.24; P!0.01) and percentage (RZ0.24; P!0.01), as well as waist circumference (RZ0.26; P!0.01). Additionally, plasma insulin and homeostasis model assessment of insulin resistance (HOMA-IR) values were related to FGF21 levels (RZ0.44; P!0.001 and RZ0.19; P!0.05 respectively). In multiple regression analysis, circulating FGF21 level variability was explained by HOMA-IR values and fat percentage, as well as waist circumference, but not correlated with oestradiol levels and free androgen index values. Conclusions: Higher circulating FGF21 levels are related to nutritional status and insulin resistance independent of PCOS. Increased FGF21 is associated with metabolic but not hormonal disturbances.

show abstract